A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
about
DNA Repair and Cytokines: TGF-β, IL-6, and Thrombopoietin as Different Biomarkers of RadioresistanceUpdate and new approaches in the treatment of Castleman diseaseEmerging treatments in Castleman disease - a critical appraisal of siltuximabPotential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancerTargeting interleukin-6 for noninfectious uveitisDevelopment of Novel Immunotherapies for Multiple MyelomaTargeting microenvironment in cancer therapeuticsReview of siltuximab in the treatment of multicentric Castleman's diseaseEvaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma.A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma.Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trialHepcidin antagonists for potential treatments of disorders with hepcidin excess.Chronic inflammation and cytokines in the tumor microenvironment.Genetic modulation of the interleukin 6 (IL-6) system in patients with advanced gastric cancer: a background for an alternative target therapy.The relationship between pro-inflammatory cytokines and pain, appetite and fatigue in patients with advanced cancer.Toll-Like Receptors and Cancer: MYD88 Mutation and Inflammation.Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma.Impact of interleukin-6 in hematological malignancies.Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman diseaseThe development of potential antibody-based therapies for myelomaEpisodic fevers and vasodilatory shock mimicking urosepsis in a patient with HIV-associated multicentric Castleman's Disease: a case report.Insight into early-phase trials for lung cancer in the United StatesDissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunitiesA phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.Modulation of hepcidin to treat iron deregulation: potential clinical applications.Cancer prevention and therapy through the modulation of the tumor microenvironment.Clear cell carcinoma of ovary and uterus.Manipulation of the hepcidin pathway for therapeutic purposes.Immunotherapy for multiple myeloma.The use of monoclonal antibodies to treat Castleman's disease.The pathophysiology and pharmacology of hepcidin.The skinny on obesity and plasma cell myeloma: a review of the literature.Siltuximab: first global approval.IL-6 blockade in chronic inflammatory diseases.Clinical development of siltuximab.Emerging strategies for cancer immunoprevention.Siltuximab: A Review in Idiopathic (Human Herpesvirus-8-Negative) Multicentric Castleman Disease.Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease.Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?
P2860
Q26738556-6A8C4FED-E3FE-4152-8C8E-48C3CD87D366Q26740703-4D54FABA-0D24-4EEE-B4F3-D463F672B7ECQ26766554-D9125927-CF5C-4C98-8642-BD17B4C512D0Q26769917-A9871BE2-9B00-4B11-9F23-E2C8C3B310D1Q26782493-48B620E6-E2AD-4E70-AA6F-40DFF8944E54Q28066890-0476BFE7-E377-4DCC-822E-32E01A288BAFQ28067219-C63E239A-FA9B-4CF2-BCF6-B4590878DC80Q28067246-97D41C79-3D79-4847-9CAC-0F46F7523763Q33411075-D86203E8-8E03-48D8-B862-30AC0BBA6772Q33418036-157C9D29-44CD-497E-881D-06DDE448ADACQ33420197-75E1F3DC-A8EC-4743-875C-D3B5420D0C9EQ33429980-1719C512-4509-4536-AFFC-5058398DDF9FQ33563777-215CAD3B-71A7-4493-AEE9-A1682145684DQ33678275-97AB9B8F-BDBF-4370-92C8-E43F83761EE5Q33714950-15721AA1-4DC2-42FA-8D94-64C1C63EFFDBQ33727960-CA7EE7F6-4940-4F52-A510-CF700D3AFA03Q33978723-ED21C59F-85A5-4D72-AE8B-041BA112886DQ34009070-0F615EC2-EE43-48D3-AB3C-5D6704F3476BQ34387624-242EAC91-A2AC-4F21-97E7-D2449ED9392DQ34636851-CBF59087-D21C-46D1-B1F0-18CF23A7A72DQ35788245-E4B1B9E2-E72A-4458-B307-B7037392CBFAQ35910542-FA7CCF14-2EAD-4307-84BC-E1A688FA1E48Q36121135-8307E82A-A490-469C-AA58-EFFADC33AA70Q36447553-3ECA4946-479A-4D87-8F0A-756DB2861CE1Q36557611-41D4BA08-0D05-48FD-92FF-8C1166F801B4Q36847852-4BFEDCCD-E7D6-403F-AEA8-65C895E1CD73Q37058267-30F3FA07-C6B3-40F3-A6AE-1CF0340F5A03Q38151508-8EC3FA4E-90FC-4BE1-B2B7-B7465A3CE48CQ38159513-8026E709-7AD4-4733-9BB0-CA070B60E1C0Q38177879-1098A2B0-7555-4163-8B06-10C01CE6D2E0Q38184651-02AE3BF8-6009-4753-91D0-2A1BAEDF7CC7Q38189504-B28B2EEE-5D1C-4E9E-96EF-2B559E43B8E4Q38211267-D1EE3F90-5C78-4F2D-AC04-7C9C1FD15925Q38222680-8A8F15D7-B921-4FA4-9468-2AD676FCF3D5Q38261783-D409601B-1A76-4DB8-8E46-CA551AE9CB2DQ38489678-55615818-EA43-446C-BD17-383B3B10F59FQ38585850-813B1DE9-71B5-49CC-A3D2-AF97027DDE08Q38591052-4520B2D6-EAE5-40C9-ACF1-30C4F81FE4BDQ38658328-C4855DD5-B105-481D-A506-A30154F790A4Q38737970-D6F1AD56-16C6-4D82-9AA6-BC513B611561
P2860
A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
A phase I, open-label study of ...... myeloma, or Castleman disease.
@ast
A phase I, open-label study of ...... myeloma, or Castleman disease.
@en
type
label
A phase I, open-label study of ...... myeloma, or Castleman disease.
@ast
A phase I, open-label study of ...... myeloma, or Castleman disease.
@en
prefLabel
A phase I, open-label study of ...... myeloma, or Castleman disease.
@ast
A phase I, open-label study of ...... myeloma, or Castleman disease.
@en
P2093
P50
P1476
A phase I, open-label study of ...... myeloma, or Castleman disease.
@en
P2093
Brett Hall
Corey Casper
Helgi van de Velde
Hossein Borghaei
Lubomir Sokol
Luis Fayad
Manjula Reddy
Peter M Voorhees
Richard R Furman
P304
P356
10.1158/1078-0432.CCR-12-3349
P407
P577
2013-05-09T00:00:00Z